[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2288944A1 - Polynucleotides et polypeptides d'enterococcus faecalis - Google Patents

Polynucleotides et polypeptides d'enterococcus faecalis Download PDF

Info

Publication number
CA2288944A1
CA2288944A1 CA002288944A CA2288944A CA2288944A1 CA 2288944 A1 CA2288944 A1 CA 2288944A1 CA 002288944 A CA002288944 A CA 002288944A CA 2288944 A CA2288944 A CA 2288944A CA 2288944 A1 CA2288944 A1 CA 2288944A1
Authority
CA
Canada
Prior art keywords
sequence
present
fragments
faecalis
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002288944A
Other languages
English (en)
Inventor
Charles A. Kunsch
Patrick J. Dillon
Steven C. Barash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2288944A1 publication Critical patent/CA2288944A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cette invention, qui a trait à des séquences polynucléotidiques du génome d'Enterococcus faecalis, à des séquences polypeptidiques codées par les séquences polynucléotidiques, aux polynucléotides et polypeptides correspondants, ainsi qu'à des vecteurs et à des hôtes comportant les polynucléotides, porte également sur des épreuves les concernant et d'autres utilisations qui en sont faites. Elle concerne, de surcroît, une information relative aux séquences polynucléotidiques et polypeptidiques stockées sur des supports informatiques ainsi que des systèmes et des méthodes informatiques facilitant leur utilisation.
CA002288944A 1997-05-06 1998-05-04 Polynucleotides et polypeptides d'enterococcus faecalis Abandoned CA2288944A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US4403197P 1997-05-06 1997-05-06
US60/044,031 1997-05-06
US4665597P 1997-05-16 1997-05-16
US60/046,655 1997-05-16
US6600997P 1997-11-14 1997-11-14
US60/066,009 1997-11-14
PCT/US1998/008985 WO1998050555A2 (fr) 1997-05-06 1998-05-04 POLYNUCLEOTIDES ET POLYPEPTIDES D'$i(ENTEROCOCCUS FAECALIS)

Publications (1)

Publication Number Publication Date
CA2288944A1 true CA2288944A1 (fr) 1998-11-12

Family

ID=27366427

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002288944A Abandoned CA2288944A1 (fr) 1997-05-06 1998-05-04 Polynucleotides et polypeptides d'enterococcus faecalis
CA002289116A Abandoned CA2289116A1 (fr) 1997-05-06 1998-05-04 Polynucleotides et polypeptides d'enterococcus faecalis

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002289116A Abandoned CA2289116A1 (fr) 1997-05-06 1998-05-04 Polynucleotides et polypeptides d'enterococcus faecalis

Country Status (8)

Country Link
US (3) US6448043B1 (fr)
EP (2) EP0981625A2 (fr)
JP (2) JP2002529046A (fr)
KR (2) KR20010012223A (fr)
CN (1) CN1268178A (fr)
AU (2) AU735444B2 (fr)
CA (2) CA2288944A1 (fr)
WO (2) WO1998050554A2 (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905670B2 (en) 1995-03-28 2005-06-14 The General Hospital Corporation Methods of screening compounds useful for prevention of infection or pathogenicity
US5834276A (en) * 1996-04-18 1998-11-10 Smithkline Beecham Corporation Asparaginyl TRNA synthetase polynucleotides of streptococcus
US6165989A (en) 1996-05-14 2000-12-26 Smithkline Beecham Corporation Era of Streptococcus pneumoniae
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
AU8921598A (en) * 1997-08-29 1999-03-16 Human Genome Sciences, Inc. 29 human secreted proteins
AU784043B2 (en) * 1999-04-15 2006-01-19 Regents Of The University Of California, The Identification of sortase gene
US7101692B2 (en) 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
US6908994B1 (en) * 1999-05-10 2005-06-21 The Texas A&M University System Collagen-binding proteins from enterococcal bacteria
WO2001034810A2 (fr) 1999-11-09 2001-05-17 Elitra Pharmaceuticals, Inc. Genes indispensables a une proliferation microbienne et antisens a cet egard
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
WO2001055178A2 (fr) 2000-01-25 2001-08-02 Genentech, Inc. Compositions et methodes de traitement de cancer
US7078584B2 (en) 2000-03-17 2006-07-18 The General Hospital Corporation Salmonella typhimurium-infected Caenorhabditis elegans for identifying inhibitors of infection
KR20020097200A (ko) * 2000-03-21 2002-12-31 엘리트라 파마슈티컬즈, 인코포레이티드 원핵세포에서의 필수유전자의 동정
EP1360315A2 (fr) * 2000-04-06 2003-11-12 PHARMACIA & UPJOHN COMPANY Procedes et materiaux antimicrobiens
US7112716B2 (en) 2000-04-06 2006-09-26 The General Hospital Corporation Methods for screening and identifying host pathogen defense genes
AU2001253508A1 (en) * 2000-04-14 2001-10-30 Phytera, Inc. Mdr efflux pumps
WO2002006491A1 (fr) * 2000-07-18 2002-01-24 Center For Advanced Science And Technology Incubation, Ltd. Isopentenyl pyrophosphate isomerase
WO2002012294A2 (fr) 2000-08-08 2002-02-14 St. Jude Children's Research Hospital Acides nucleiques de streptocoque de groupe b, polypeptides, compositions therapeutiques et vaccins correspondants
US7892552B2 (en) 2001-08-08 2011-02-22 University Of Utah Research Foundation Group B Streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
US20020120408A1 (en) * 2000-09-06 2002-08-29 Kreiswirth Barry N. System and method for tracking and controlling infections
US7349808B1 (en) 2000-09-06 2008-03-25 Egenomics, Inc. System and method for tracking and controlling infections
NZ540544A (en) * 2000-10-27 2007-08-31 Inst Genomic Research Nucleic acids and proteins from streptococcus groups A & B
EP1227152A1 (fr) * 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Souche bactérienne et genome de bifidobacterium
AU2002365113A1 (en) * 2001-07-18 2003-07-15 The General Hospital Corporation Enterococcal virulence factors
US6696254B2 (en) * 2001-11-21 2004-02-24 Kimberly-Clark Worldwide, Inc. Detection and identification of enteric bacteria
WO2004011491A2 (fr) * 2002-07-31 2004-02-05 Affinium Pharmaceuticals, Inc. Polypeptides purifies d'enterococcus faecalis
WO2004013167A2 (fr) * 2002-08-01 2004-02-12 Affinium Pharmaceuticals, Inc. Nouveaux polypeptides purifies issus d'enterococcus faecalis
EP1597348A4 (fr) * 2002-08-26 2010-03-31 Novartis Vaccines & Diagnostic Genomes de streptocoques conserves ou specifiques
WO2004025416A2 (fr) * 2002-09-13 2004-03-25 The Texas A & M University System Procede bio-informatique destine a identifier les proteines ancrees en surface provenant des bacteries gram positif et proteines obtenues par ce procede
AU2003280250A1 (en) * 2002-11-05 2004-06-07 Affinium Pharmaceuticals, Inc. Crystal structures of bacterial thymidylate kinases
AU2003280249A1 (en) * 2002-11-05 2004-06-07 Affinium Pharmaceuticals, Inc. Crystal structures of bacterial guanylate kinases
WO2004042043A2 (fr) * 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Structures cristallines de 3-epimerases bacteriennes de ribulose-phosphate
CA2505038C (fr) * 2002-12-06 2014-07-15 Innogenetics N.V. Detection, identification et differenciation de taxa eubacteries, par dosage biologique d'hybridation
JP4399211B2 (ja) * 2002-12-21 2010-01-13 株式会社ハイニックスセミコンダクター バイオセンサー
CN102304527A (zh) * 2003-05-30 2012-01-04 英特塞尔股份公司 肠球菌抗原
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US7723474B2 (en) * 2003-10-21 2010-05-25 The Regents Of The University Of California Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
CA2575548A1 (fr) 2004-07-29 2006-07-27 John L. Telford Compositions immunogenes pour bacteries a gram positif telles que streptococcus agalactiae
EP1807446A2 (fr) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Compositions immunogenes et therapeutiques pour streptococcus pyogenes
JP2008537878A (ja) 2005-03-18 2008-10-02 マイクロビア， インコーポレイテッド 含油性酵母および真菌におけるカロテノイドの産生
MX2008003156A (es) * 2005-09-06 2008-09-11 Biogreen As Brotes de lino sin mucilago y sus derivados asi como tambien la produccion y aplicacion de los mismos.
US20070059714A1 (en) * 2005-09-12 2007-03-15 Birgit Strommenger Detection of presence and antibiotic susceptibility of enterococci
EP2054431B1 (fr) * 2006-06-09 2011-08-31 Novartis AG Conformères d'adhésines bactériennes
WO2008042338A2 (fr) 2006-09-28 2008-04-10 Microbia, Inc. Production de caroténoïdes dans des levures et des champignons oléagineux
US20110038879A1 (en) * 2006-10-30 2011-02-17 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
KR101621837B1 (ko) 2007-09-12 2016-05-17 노파르티스 아게 Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
PL2235046T3 (pl) * 2007-12-21 2012-12-31 Novartis Ag Zmutowane formy streptolizyny O
US20110105383A1 (en) * 2008-09-10 2011-05-05 Magnus Hook Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
US8883174B2 (en) 2009-03-25 2014-11-11 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
BRPI1011919A2 (pt) 2009-06-29 2017-09-26 Childrens Medical Center vacinas e composições contra streptococcus pneumoniae
EP2563380B1 (fr) 2010-04-26 2018-05-30 aTyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps se rapportant à des fragments protéiques de la cystéinyl-arnt synthétase
EP2563381B1 (fr) 2010-04-27 2017-08-09 aTyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps se rapportant à des fragments protéiques d'isoleucyl arnt synthétases
WO2011139801A2 (fr) 2010-04-27 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps se rapportant à des fragments protéiques de thréonyl arnt synthétases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
JP6008838B2 (ja) 2010-04-29 2016-10-19 エータイアー ファーマ， インコーポレイテッド アスパラギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US9034320B2 (en) 2010-04-29 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
WO2011150279A2 (fr) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps liées à fragments protéiques de glutaminyl-arnt synthétases
WO2011140132A2 (fr) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de phénylalanyl-alpha-arnt-synthétases
EP2566515B1 (fr) 2010-05-03 2017-08-02 aTyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps liées à des fragments protéiques d'arginyle-arnt synthétases
EP2566516B1 (fr) 2010-05-03 2019-07-03 aTyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic et d'anticorps liées à des fragments protéiques de séryle-arnt synthétases
CN103140233B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
EP2566499B1 (fr) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, diagnostiques et à base d'anticorps liées à des fragments protéiques de complexe multi-arnt synthétase p38
CN103096909A (zh) 2010-05-04 2013-05-08 Atyr医药公司 与谷氨酰-脯氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2799197C (fr) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Decouverte de compositions inedites de nature therapeutique, diagnostique et a base d'anticorps contenant des fragments proteiques de phenylalanyl-beta-arnt synthetases
WO2011146410A2 (fr) 2010-05-17 2011-11-24 Atyr Pharma, Inc. Découverte innovante de compositions thérapeutiques, de diagnostic, et d'anticorps associées à des fragments protéiques de leucyl-arnt synthétases
CN103118694B (zh) 2010-06-01 2016-08-03 Atyr医药公司 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
WO2012021247A2 (fr) 2010-07-12 2012-02-16 Atyr Pharma, Inc. DÉCOUVERTE INNOVANTE DE COMPOSITIONS THÉRAPEUTIQUES, DE DIAGNOSTIC ET D'ANTICORPS SE RAPPORTANT À DES FRAGMENTS PROTÉIQUES DE GLYCYL-ARNt SYNTHÉTASES
JP5991973B2 (ja) 2010-07-12 2016-09-14 エータイアー ファーマ， インコーポレイテッド アスパルチルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
ES2653718T3 (es) 2010-07-12 2018-02-08 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de histidil-ARNt sintetasas
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
ES2645019T3 (es) 2010-10-06 2017-12-01 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de triptofanil-ARNt sintetasas
MY163871A (en) 2011-01-20 2017-10-31 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
WO2013022982A2 (fr) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Polypeptides tyrosyl-arnt synthétase pégylés
CN102286417B (zh) * 2011-09-09 2013-04-10 宜春强微生物科技有限公司 高密度粪肠球菌及其发酵培养工艺
WO2013086216A1 (fr) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Aspartyl-arnt synthétases améliorées
WO2013086228A1 (fr) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Polypeptides aspartyl-arnt synthétase pégylés
US9688978B2 (en) 2011-12-29 2017-06-27 Atyr Pharma, Inc. Aspartyl-tRNA synthetase-Fc conjugates
EP2872535A1 (fr) 2012-07-16 2015-05-20 Pfizer Inc. Saccharides et leurs utilisations
EP2970921B1 (fr) 2013-03-15 2018-09-19 aTyr Pharma, Inc. Conjugués histidyl-arnt synthétase-région fc
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
KR102630655B1 (ko) 2016-03-31 2024-01-30 엔지엠 바이오파마슈티컬스, 아이엔씨. 결합 단백질 및 이의 사용 방법
CN106244714B (zh) * 2016-09-23 2019-09-24 山西大学 一种巨大芽孢杆菌特异性检测的基因芯片
CN106978380A (zh) * 2016-12-14 2017-07-25 天津科技大学 一株高木糖耐性肺炎克雷伯氏菌株及其构建方法
US11767520B2 (en) 2017-04-20 2023-09-26 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
CN107526942B (zh) * 2017-07-18 2021-04-20 中山大学 生命组学序列数据的反向检索方法
KR101996079B1 (ko) * 2017-10-13 2019-07-03 연세대학교 원주산학협력단 엔테로코커스 패칼리스를 유효성분으로 함유하는 탈모 예방 또는 치료용 조성물
CN108776221B (zh) * 2018-06-06 2020-07-31 中国农业大学 一种禽白血病病毒抗体和鸡白痢沙门氏菌抗体同时检测的试剂盒
CN109182240B (zh) * 2018-09-18 2021-06-25 绿康生化股份有限公司 地衣芽孢杆菌DW2ΔphoP在杆菌肽生产中的应用
CN110423832A (zh) * 2019-08-28 2019-11-08 华南理工大学 一种基于特异性基因靶标lmo0160的单增李斯特菌的PCR检测引物
CN110964672B (zh) * 2019-12-29 2022-09-02 江南大学 戊糖片球菌ccfm1104、其发酵食品及应用
CN114686562B (zh) * 2020-12-28 2024-04-30 广东菲鹏生物有限公司 用于核酸样本扩增的组合物、试剂盒、方法及系统
CN114540521B (zh) * 2022-03-23 2022-09-02 广东省科学院微生物研究所(广东省微生物分析检测中心) 具有降糖降脂功效的植物乳杆菌84-3特异性分子靶标及其检测方法
WO2023205627A1 (fr) * 2022-04-18 2023-10-26 Vaxcyte, Inc. Vaccin enterococcus faecalis et ses utilisations
CN115322975B (zh) * 2022-06-16 2023-04-25 扬州大学 路德维希肠杆菌氧化还原酶的突变体及其应用
CN116199750A (zh) * 2023-01-06 2023-06-02 吉林大学 一种核糖体蛋白s11及制备方法和在疫苗佐剂中的应用
CN117778439A (zh) * 2024-01-03 2024-03-29 天津大学 一种产林可霉素的基因工程菌及构建方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1160334T3 (da) * 1992-07-07 2007-01-08 Fuso Pharmaceutical Ind Probe til diagnostisering af infektionssygdom, der opstår fra Pseudomonas aeruginosa
JPH11501520A (ja) 1995-04-21 1999-02-09 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド インフルエンザ菌Ｒｄゲノムのヌクレオチド配列、そのフラグメント及びその使用
US6537773B1 (en) * 1995-06-07 2003-03-25 The Institute For Genomic Research Nucleotide sequence of the mycoplasma genitalium genome, fragments thereof, and uses thereof
AU5128000A (en) 1999-05-10 2000-11-21 The Texas A & M University System Collagen-binding proteins from enterococcal bacteria

Also Published As

Publication number Publication date
AU7280598A (en) 1998-11-27
CN1268178A (zh) 2000-09-27
WO1998050555A2 (fr) 1998-11-12
AU745787B2 (en) 2002-03-28
JP2002529046A (ja) 2002-09-03
EP1002090A2 (fr) 2000-05-24
AU7279398A (en) 1998-11-27
WO1998050554A3 (fr) 1999-04-01
KR20010012223A (ko) 2001-02-15
EP0981625A2 (fr) 2000-03-01
US20020045737A1 (en) 2002-04-18
WO1998050554A2 (fr) 1998-11-12
JP2002516571A (ja) 2002-06-04
US6448043B1 (en) 2002-09-10
US20050043528A1 (en) 2005-02-24
WO1998050555A3 (fr) 1999-01-14
KR20010012236A (ko) 2001-02-15
US20030017495A1 (en) 2003-01-23
US6913907B2 (en) 2005-07-05
AU735444B2 (en) 2001-07-05
CA2289116A1 (fr) 1998-11-12

Similar Documents

Publication Publication Date Title
CA2288944A1 (fr) Polynucleotides et polypeptides d'enterococcus faecalis
Shull et al. Amino-acid sequence of the β-subunit of the (Na++ K+) ATPase deduced from a cDNA
EP2261358B1 (fr) Antigènes de Streptococcus
CA2321106C (fr) Antigenes du streptocoque du groupe b
US6217884B1 (en) Streptococcus pneumoniae 37-kDa surface adhesin a protein
US7635482B2 (en) Streptococcus antigens
AU2011200622A1 (en) Streptococcus Pneumoniae Antigens and Vaccines
US6537773B1 (en) Nucleotide sequence of the mycoplasma genitalium genome, fragments thereof, and uses thereof
AU8151898A (en) Lyme disease vaccines
CA2182206A1 (fr) Proteines humaines de reparation par non complementarite d'adn
JP2002027991A (ja) コクシジオーシス鶏ワクチン
JP2001503616A (ja) 新規ランチオニン抗生物質組成物および方法
AU764811B2 (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein A truncate, vaccine derived therefrom and uses thereof
WO2000021989A9 (fr) Proteines dbp a et b liant la decorine et gene codant pour elles
CA2296814A1 (fr) Polynucleotides et sequences de treponema pallidium
JP2002514425A (ja) モラクセラ・カタラーリス（Ｍｏｒａｘｅｌｌａｃａｔａｒｒｈａｌｉｓ）由来の化合物
AU2000253239A1 (en) Bartonella henselae virb operon and proteins encoded thereby
JP2002517199A (ja) モラクセラ・カタラーリス（Ｍｏｒａｘｅｌｌａｃａｔａｒｒｈａｌｉｓ）由来のＢＡＳＢ０２７タンパク質およびＢＡＳＢ０２７遺伝子、抗原、抗体、ならびに使用
JPH11508453A (ja) Ｉｌ―１６活性を有するプロセスされたポリペプチド、それらの製法、及びそれらの使用
JP4727059B2 (ja) ＢａｂｅｓｉａｇｉｂｓｏｎｉＰ５０抗原をコードする核酸分子とその発現産物の利用
AU2010227084B2 (en) Group B Streptococcus Antigens
AU2005209689B2 (en) Novel streptococcus antigens
AU2007200130B2 (en) Group B Streptococcus Antigens
WO2000061165A1 (fr) Motif d'adhesine conserve et ses procedes d'utilisation
CA2223395A1 (fr) Sequences d'acide nucleique et d'acides amines concernant helicobacter pylori, utilisees a des fins diagnostiques et therapeutiques

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead